睿知中国医院研究地图
候选清单

即将招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海市肺科医院Shanghai Pulmonary Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06585644,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 1

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(1 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06585644,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

Inclusion Criteria: 1) EGFR mutation-positive (including 19Del and 21L858R) non-small cell lung cancer (NSCLC) confirmed by biopsy; 2) Resectable stage II-III NSCLC confirmed by chest CT, PET-CT, and/or EBUS; 3) Absence of distant metastasis (including head MRI, whole-body bone scan, PET-CT, CT of liver and adrenal glands); 4) The patient exhibits good pulmonary function and is deemed suitable for surgical intervention; 5) Aged 18 and above; 6)At least one measurable tumor lesion (with a longest diameter of 10mm or more as measured by CT); 7) The ECOG score ranges from 0 to 1; 8) Women of childbearing age must undergo a pregnancy test within 7 days prior to treatment, and the result must be negative. During the trial period and for 30 days following its conclusion, reliable contraceptive measures such as intrauterine devices, oral contraceptives, and condoms should be utilized. Additionally, men of reproductive age should use condoms for contraception during the trial period and for 30 days after its completion; 9) The other major organs (liver, kidneys, hematological system, etc.) are functioning normally. Hemoglobin is ≥9.0 g/dL (or can be maintained or exceeded through treatments such as blood transfusions); the red blood cell count is ≥2.0×10\^9/L; the absolute neutrophil count is ≥1.0×10\^9/L; the platelet count is ≥100×10\^9/L; total bilirubin levels are within the normal range; AST, ALT, and alkaline phosphatase levels are ≤2.5 times the upper limit of normal; creatinine level is ≤2.0 mg/dL; creatinine clearance rate is ≥60 ml/min; patients who have not received anticoagulant therapy should have a prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 times the upper limit of normal, while patients who have undergone comprehensive or intravenous anticoagulant therapy are eligible for clinical trials only if they have maintained stable anticoagulant drug dosages for at least 2 weeks and their coagulation test results fall within the target therapeutic range; 10) The patient is required to sign an informed consent form. Exclusion Criteria: 1) The patient has undergone comprehensive anti-cancer treatment for non-small cell lung cancer, including surgical intervention, local radiotherapy, cytotoxic drug therapy, and targeted drug therapy; 2) The patient had no history of any cancer other than small cell lung cancer within the 5 years prior to the trial, with the exception of in situ cervical cancer, cured basal cell carcinoma, and bladder epithelial neoplasms (including Ta and Tis); 3) The patient has any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, recent onset of angina within the past 3 months, congestive heart failure [≥ NYHA Class II], myocardial infarction (within the past 6 months), severe arrhythmia, and liver, kidney or metabolic disorders requiring drug therapy); 4) The patient is a carrier of active hepatitis B, hepatitis C, or HIV; 5) Patients with severe or newly developed gastrointestinal diseases presenting diarrhea as the primary symptom; 6) The patient is receiving treatment with a P-glycoprotein inhibitor; 7) Patients with a history of or current cardiovascular malformations; 8) Patients with a history of or currently suffering from interstitial lung disease; 9) Patients who have undergone major systemic surgery or experienced severe trauma within the three months prior to the trial; 10) Those afflicted with neurological disorders or psychiatric illnesses; 11) Patients experiencing malabsorption conditions; 12) Female patients who are pregnant or lactating; 13) Other situations where researchers deem the patient unsuitable for enrollment. Withdrawal Criteria: In the following cases, the patient will withdraw from the trial: 1) The patient himself or his legal representative requests withdrawal; 2) The investigator believes that the patient\'s continued participation in the study will be harmful to their health; 3) The patient has developed a severe allergic reaction to the chemotherapy drug, such as grade 3-4 exfoliative dermatitis or anaphylaxis; 4) There is any other serious adverse reaction, and the principal investigator (PI) or a PI-designated investigator deems it necessary to suspend treatment; 5) The patient\'s compliance is very poor; 6) The patient\'s β-HCG test result suggests pregnancy; 7) During the study period, the patient develops another disease. The investigator believes that the disease will significantly affect the evaluation of the patient\'s clinical condition and it is necessary to terminate the treatment plan; 8) The patient is found to have another malignant tumor that needs to be treated; 9) The patient is lost to follow-up; 10) The patient has taken illicit drugs or other substances judged by the investigator to be likely to cause toxicity or lead to a bias in the study results; 11) The patient dies. Patients who withdraw from the trial should have the reason for withdrawal documented in both the case report form and the patient\'s medical record. Follow-up should be conducted for all patients who withdraw due to adverse events or abnormal laboratory test results, until the adverse event is resolved or stabilized, and subsequent outcomes of the adverse events should be recorded. In cases where a patient dies during the course of the trial or within 28 days after its conclusion, it is incumbent upon the investigator to notify the sponsor. The cause of death must be meticulously detailed in the serious adverse event (SAE) report form and submitted to the ethics committee within 24 hours.

引自 ClinicalTrials.gov, NCT06585644, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06585644,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06585644